Gewinn- und Verlustrechnung von OPKO Health

zacks.com2026-08-19 13:51:09

OPK Raises $125 Million Against Royalties: What Investors Should Know

OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.

zacks.com2026-08-19 13:41:04

Is OPK Worth Buying as Valuation Meets Improving Business Trends?

OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.

zacks.com2026-08-19 13:36:07

OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?

OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.

zacks.com2026-08-18 14:26:06

OPKO Health Secures $125 Million Financing Against Mazdutide Royalties

OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.

globenewswire.com2026-08-13 09:15:00

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside

seekingalpha.com2026-08-04 13:55:48

OPKO Health: Mazdutide And MDX-2201 Could Change Everything

On July 27, OPKO Health, Inc. released its Q2 numbers. So, OPK's revenue from transfer of IP and other increased 208% YoY to $46.1 million in Q2, driven by a Nicoya license amendment. Also, OPKO raised its full-year 2026 revenue guidance from $530-$560 million to $560-$585 million.

zacks.com2026-08-04 13:01:08

OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know

OPKO Health (OPK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.